Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization
Recruiting
N/A
Interventional Study
Corneal Neovascularisation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 51 (estimated)
- Sponsor
- HoChiMinh City Eye Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization.
The main questions it aims to answer are:
Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well toler…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age over 18 years.
* Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
* Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
* Agreement to participate in the study …
Contacts